1. Academic Validation
  2. Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer

Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer

  • Adv Sci (Weinh). 2025 Jan 31:e2408845. doi: 10.1002/advs.202408845.
Zhou Yang 1 2 Wei Su 2 3 Qinglin Zhang 4 Lili Niu 5 Baijie Feng 6 Yu Zhang 1 2 Feng Huang 7 Jiaxin He 7 Qinyao Zhou 7 Xin Zhou 7 Longjun Ma 8 Jingwan Zhou 7 Yuanrong Wang 7 Wenjing Xiong 7 Jun Xiang 1 2 Zhilin Hu 9 Qiang Zhan 4 Bing Yao 7 10
Affiliations

Affiliations

  • 1 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • 3 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • 4 Departments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu, 214043, China.
  • 5 Department of Integrative Medicine, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, 200433, China.
  • 6 Department of Medical Oncology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, China.
  • 7 Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine; National Experimental Teaching Center of Basic Medical Science, Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, 211166, China.
  • 8 Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
  • 9 Department of Immunology, Key Laboratory of Immune Microenvironment and Disease, The School of Basic Medicine; Department of laboratory medicine, the first affiliated hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, 211166, China.
  • 10 State Key Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine; NHC Key Laboratory of Antibody Technique, Jiangsu Province Engineering Research Center of Antibody Drug, Nanjing Medical University, Nanjing, 211166, China.
Abstract

Colorectal Cancer (CRC) is highly resistant to Ferroptosis, which hinders the application of anti-ferroptosis therapy. Through drug screening, it is found that histone deacetylase inhibitor (HDACi) significantly sensitized CRC to Ferroptosis. The combination of HDACi and Ferroptosis inducers synergically suppresses CRC growth both in vivo and in vitro. Mechanically, HDACi reduces Ferroptosis suppressor protein (FSP1) by promoting its mRNA degradation. Specifically, it is confirmed that HDACi specifically targets HDAC1 and promotes the H3K27ac modification of fat mass- and obesity-associated gene (FTO) and AlkB Homolog 5, RNA Demethylase (ALKBH5), which results in significant activation of FTO and ALKBH5. The activation of FTO and ALKBH5 reduces N6-methyladenosine (m6A) modification on FSP1 mRNA, leading to its degradation. Crucially, lactylation of HDAC1K412 is essential for Ferroptosis regulation. Both Vorinostat (SAHA) and Trichostatin A (TSA) notably diminish HDAC1K412 lactylation in comparison to other HDAC1 inhibitors, exhibiting a consistent trend of increasing susceptibility to Ferroptosis. In conclusion, the research reveals that HDACi decreases HDAC1K412 lactylation to sensitize CRC to Ferroptosis and that the combination of HDACi and Ferroptosis inducers can be a promising therapeutic strategy for CRC.

Keywords

HDAC inhibitor; N6‐methyladenosine modification; colorectal cancer; ferroptosis; lactylation.

Figures
Products